---
figid: PMC8778800__life-12-00081-g001
figtitle: 'FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?'
organisms:
- Homo sapiens
- Mus musculus
- Helicobacter pylori
- NA
pmcid: PMC8778800
filename: life-12-00081-g001.jpg
figlink: /pmc/articles/PMC8778800/figure/life-12-00081-f001/
number: F1
caption: 'FGFR structure and pathway. (a) FGFR structure: FGFR contains three extracellular
  Ig domains (domains I, II, and III), a single transmembrane helix domain and an
  intracellular tyrosine kinase domain. The acidic box region between Ig I and II
  domains can interact with substances other than FGFs. The FGF binding sites are
  located in domains II and III. For FGFR1-3, the alternative splicing of the second
  half of the Ig III domain is tissue-dependent. In the case of FGFR4, FGFR contains
  a single homologous FGFR-IIIc isoform. (b) FGFR pathway: Activation of the FGFR
  tyrosine kinase domain may activate several cellular pathways, including the RAS-RAF-MEK-ERK,
  the PIK3CA-AKT-mTOR, and the JAK pathways through the FGFR-associated cytosolic
  docking protein FRS2.'
papertitle: 'FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?.'
reftext: Csongor G. Lengyel, et al. Life (Basel). 2022 Jan;12(1):81.
year: '2022'
doi: 10.3390/life12010081
journal_title: Life
journal_nlm_ta: Life (Basel)
publisher_name: MDPI
keywords: fibroblast growth factor receptors | FGFR fusions | next generation sequencing
  | first line | target therapy | FGFR inhibitors | Tyrosine kinase inhibitors | precision
  medicine | bemarituzumab
automl_pathway: 0.9048297
figid_alias: PMC8778800__F1
figtype: Figure
organisms_ner:
- Mus musculus
- Homo sapiens
redirect_from: /figures/PMC8778800__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8778800__life-12-00081-g001.html
  '@type': Dataset
  description: 'FGFR structure and pathway. (a) FGFR structure: FGFR contains three
    extracellular Ig domains (domains I, II, and III), a single transmembrane helix
    domain and an intracellular tyrosine kinase domain. The acidic box region between
    Ig I and II domains can interact with substances other than FGFs. The FGF binding
    sites are located in domains II and III. For FGFR1-3, the alternative splicing
    of the second half of the Ig III domain is tissue-dependent. In the case of FGFR4,
    FGFR contains a single homologous FGFR-IIIc isoform. (b) FGFR pathway: Activation
    of the FGFR tyrosine kinase domain may activate several cellular pathways, including
    the RAS-RAF-MEK-ERK, the PIK3CA-AKT-mTOR, and the JAK pathways through the FGFR-associated
    cytosolic docking protein FRS2.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Il1a
  - tm
  - tk
  - Frs2
  - Grb2
  - ras
  - Hras
  - Kras
  - Rem1
  - Zhx2
  - Mdk
  - Ephb2
  - Mapk1
  - Gab1
  - Pik3ca
  - Akt1
  - Mtor
  - IL1A
  - TK1
  - TK2
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - PLCG1
  - PLCG2
  - FRS2
  - GRB2
  - XYLT2
  - SOS1
  - SOS2
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - GAB1
  - PIGU
  - PIK3CA
  - AKT1
  - AKT2
  - AKT3
  - MTOR
---
